NCT05919797View on ClinicalTrials.gov

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 8, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Obesity
Interventions
DRUG

Naltrexone-Bupropion Combination

Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.

Trial Locations (1)

10032

RECRUITING

Columbia University Medical Center, New York

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Columbia University

OTHER